HUM vs IBRX · P/E 39, rev $117.76B vs rev $14.7M
Humana Inc (HUM) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported HUM revenue for 2024-12-31 was $117.76B. Net income was $1.21B. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported IBRX revenue for 2024-12-31 was $14.7M. Net income was -$413.6M. Revenue was up 2270.6% from 2023-12-31 to 2024-12-31. IBRX currently screens at market cap $7.88B.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the HUM and IBRX stock pages for the full models.
Not investment advice.